Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Capital Employed for 4 consecutive years, with 1.36% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 43.0% to 1.36% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.36%, a 43.0% decrease, with the full-year FY2025 number at 0.86%, up 4.0% from a year prior.
  • Return on Capital Employed was 1.36% for Q4 2025 at Phathom Pharmaceuticals, up from 1.4% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.58% in Q4 2023 to a low of 1.49% in Q2 2025.
  • A 4-year average of 1.01% and a median of 1.0% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 57bps in 2024, then plummeted -62bps in 2025.
  • Phathom Pharmaceuticals' Return on Capital Employed stood at 1.1% in 2022, then surged by 47bps to 0.58% in 2023, then tumbled by -60bps to 0.93% in 2024, then tumbled by -46bps to 1.36% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Return on Capital Employed are 1.36% (Q4 2025), 1.4% (Q3 2025), and 1.49% (Q2 2025).